Oklo's $1B offering raises red flags including financial setbacks, regulatory hurdles, and shifting strategies amid optimism ...

Explore REGENXBIO's RGX-121 gene therapy for Hunter syndrome, with an FDA decision due Nov 9, 2025. Click here to read my ...

The backlog for contract oil driller Valaris remains strong. Read why recent share buybacks signal management’s confidence ...

Rivian's initial promise has faded amid ongoing losses, weak BEV demand, and significant capital burn. Click here to read an ...

Within the S&P 500, 32 stocks now have market caps of at least $250 billion. Of those, four have traded at all-time highs ...

Gold broke out of its descending daily channel on Monday, supported by early-week US Dollar weakness. Click to read.

Blue Owl Capital Corporation outperforms with a 2% Q1 NAV return, solid portfolio quality, low non-accruals & first-lien ...

Explore the explosive fallout between Elon Musk and Donald Trump, from political endorsements to shocking allegations, and ...

Northern Dynasty Minerals is a 'Hold' for risk-tolerant investors amidst bullish copper/gold trends. Click here to read my ...

We asked Seeking Alpha analysts Kenio Fontes and Daniel Jones for their picks. Kenio Fontes: Two companies stand out for me ...

U.S. stock market could see potential double-digit annual returns despite being down more than 15% YTD at one point. Read ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...